Principal Consultant
Biologics Consulting Group, led by Principal Consultant Donna-Bea Tillman, offers unparalleled FDA regulatory guidance for medtech companies. With a former director of the CDRH Office of Device Evaluation at its helm and 15 years of dedicated experience, the firm has a proven track record of success, including 45 510(k) and 10 De Novo submissions. They provide comprehensive services from pathway a...
Experience: 15+ years
Submissions: 45 510(k), 10 De Novo, 5 PMA
Biologics Consulting Group provides regulatory consulting services to clients in:
Biologics Consulting Group, led by Principal Consultant Donna-Bea Tillman, offers unparalleled FDA regulatory guidance for medtech companies. With a former director of the CDRH Office of Device Evaluation at its helm and 15 years of dedicated experience, the firm has a proven track record of success...
Biologics Consulting Group emerges as a distinguished regulatory consultancy for the medtech industry, boasting a team with profound expertise and an impressive history of success. Anchored by a Principal Consultant who is a former Director of the FDA's CDRH Office of Device Evaluation, the firm provides exceptional guidance through intricate FDA pathways such as 510(k), De Novo, and PMA. With 15 years dedicated to medical device regulations, they have achieved significant milestones, successfully managing 45 510(k) and 10 De Novo submissions. Their comprehensive service suite, encompassing pathway assessments, submission authoring, and post-market support, coupled with their ability to deliver efficient, customized regulatory solutions, solidifies their role as an indispensable partner for medtech professionals navigating complex regulatory terrains.
This analysis is generated by Cruxi AI using public information and may not capture the full scope of the consultant's experience.
Share a brief overview of your device and timeline. Cruxi will forward your request to Biologics Consulting Group and help structure next steps.
Contact Now